DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

MEDP·Medpace Holdings, Inc.

$.
+. (+.%)
After Hours
High
$540.37
Open
$536.31
Market Cap
15.38B
52W High
$628.92
Low
$530.06
P. Close
$537.69
P/E
33.41
52W Low
$306.70
Fwd P/E
28.54
DailyIQ Est.
$457.96
Technical Score (1D)
91
BUY
News Sentiment
65
BULLISH
MEDP’s shares surged roughly 16% over the past month, lifting the stock above most analyst targets while still trading below several intrinsic‑value models, a move that has reignited debate over whether the market is overly cautious or overvalued. The rally has prompted investors to revisit valuation assumptions, as the company’s 1‑year total shareholder return of 66% and 5‑year return of 194% underscore its long‑term growth potential. Because the price now sits above consensus multiples, any forthcoming earnings guidance that deviates from expectations could quickly shift the valuation narrative. A modest earnings beat could reinforce the bullish case, while a miss might trigger a re‑downgrade of the stock’s valuation. The company’s clinical pipeline remains a key driver; updates on upcoming trial milestones or regulatory approvals could serve as catalysts for further price movement. Analysts are also watching for any changes in the company’s valuation metrics, such as adjusted EBITDA or free‑cash‑flow multiples, which could alter the perceived upside. Market sentiment remains cautious, with the stock still trading below some intrinsic‑value estimates, suggesting that volatility could persist in the next 1–10 trading days. Traders should keep an eye on the next earnings release for guidance on revenue growth and margin expectations. Additionally, any news regarding regulatory decisions or clinical trial results in the coming days could provide the next decisive factor for the stock’s trajectory.
Earnings Summary
Medpace Holdings, Inc. is a clinical research organization that delivers end‑to‑end drug and medical device development services across North America, Europe, and Asia, positioning itself as a full‑service partner for pharmaceutical, biotechnology, and medical device clients; it operates within the broader healthcare diagnostics and research sector. In Q4 2025 Medpace reported EPS of $4.67 versus an estimate of $4.2264, up 27% from the $3.6813 EPS of Q4 2024, and revenue of $708.45 million against an estimate of $690.93 million, a 32% increase from the $536.59 million reported in Q4 2024; both quarters saw earnings beats, with revenue also surpassing guidance in Q4 2025, indicating an acceleration in top‑line growth and a continued pattern of outperforming analyst expectations. Historically, Medpace has maintained a trajectory of rising EPS and revenue in successive quarters, consistently beating estimates when data are available, and has shown resilience in generating growth even amid market volatility, though margin pressure has been a recurring concern noted by analysts. Recent analyst commentary underscores this tension: Baird and Jefferies downgraded the stock to neutral citing slowing revenue growth and tightening margins, while Argus Research raised its target, reflecting divergent views on the company’s earnings trajectory; these mixed signals highlight investor uncertainty around the sustainability of revenue momentum and the impact of rising R&D costs. Investors should watch the upcoming earnings release for any revisions to revenue guidance, margin expectations, and commentary on backlog composition and cancellation trends, as well as updates on pipeline milestones and regulatory approvals that could influence the company’s growth outlook, with particular attention to any new contract wins or metabolic project developments that may offset perceived earnings drag.

EPS

EstBeatMiss
$2.88$3.39$3.89$4.40$4.90Q4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$4.00 - -
Q4'25$4.23$4.67+10.5%
Q4'24$3.12$3.68+18.1%

Revenue

EstBeatMiss
$511M$567M$623M$678M$734MQ4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$703M - -
Q4'25$691M$708M+2.5%
Q4'24 - $537M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MEDP Stock Snapshot

MEDP is currently trading at $538.23, giving Medpace Holdings, Inc. a market cap of 15.38B and a P/E ratio of 33.4. Today's range spans $530.06–$540.37, with shares opening at $536.31 and moving up $0.54 (0.1%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 65/100.

Over the past year MEDP has traded between $306.70 and $628.92 - the current price is +75.5% off the 52-week low and -14.4% from the high. 21 analysts cover the stock with a Hold consensus and a mean 12-month target of $451.42 (range $329.00–$547.00), implying downside of -16.1%.

Relative strength is the story for Medpace Holdings, Inc. (MEDP) in Healthcare right now. Technical score 91/100 (BUY), sentiment bullish at 65/100, price $538.23 (in the upper portion of its 52-week range). The current P/E ratio stands at 33.4. The 15.38B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $306.70–$628.92.

The combination of a BUY signal (91/100) and bullish news sentiment (65/100) puts MEDP on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 15.38B in Healthcare market cap without immediately moving the stock. At $538.23 (in the upper portion of its 52-week range in the $306.70–$628.92 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.